Autolus Therapeutics (FRA:6A3A) Inventories, Raw Materials & Components: €16.81 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
71 GF Score
Price €1.28
GF Value €17.40
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics Inventories, Raw Materials & Components?

Autolus Therapeutics FRA:6A3A -7.25% 71 Inventories, Raw Materials & Components is €16.81 Mil as of Mar. 2026. GuruFocus rates FRA:6A3A with a GF Score™ of 71/100 and a GF Value™ of €17.40 (Possible Value Trap). The stock has 7 warning signs investors should review.

Autolus Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €16.81 Mil.

Autolus Therapeutics's quarterly raw materials increased from Sep. 2025 (€14.11 Mil) to Dec. 2025 (€20.65 Mil) but then declined from Dec. 2025 (€20.65 Mil) to Mar. 2026 (€16.81 Mil).

Autolus Therapeutics's annual raw materials increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€3.80 Mil) and increased from Dec. 2024 (€3.80 Mil) to Dec. 2025 (€20.65 Mil).

Autolus Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Autolus Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autolus Therapeutics Inventories, Raw Materials & Components Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.80 20.65

Autolus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 13.56 14.11 20.65 16.81
FRA:6A3A
71GF Score
Autolus Therapeutics PLC FRA:6A3A
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autolus Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €16.81 Mil mean?
Autolus Therapeutics (FRA:6A3A) has a Inventories, Raw Materials & Components of €16.81 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Autolus Therapeutics and its competitors.
Is Autolus Therapeutics' Inventories, Raw Materials & Components too high?
Autolus Therapeutics' current Inventories, Raw Materials & Components is €16.81 Mil. Overall, Autolus Therapeutics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Inventories, Raw Materials & Components compare to FBRX and SGMT?
Autolus Therapeutics' Inventories, Raw Materials & Components of €16.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Autolus Therapeutics and its competitors. Autolus Therapeutics's current Inventories, Raw Materials & Components is €16.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €17.40, compared to a current price of €1.28 — trading 92.6% below its estimated fair value. The current Inventories, Raw Materials & Components is €16.81 Mil. Autolus Therapeutics' overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Inventories, Raw Materials & Components is €16.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.28 is trading 92.6% below its estimated GF Value™ of €17.40. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • Inventories, Raw Materials & Components: €16.81 Mil
  • GF Value™: €17.40 vs. price of €1.28 (92.6% below fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
71GF Score

Get the complete analysis for FRA:6A3A

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.28
Price
€17.40
GF Value